Cue Biopharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Cue Biopharma şirketinin kazançlarının yıllık 2.1% oranında düşmesi, yıllık gelirinin ise yıllık 33% oranında artması bekleniyor. EPS'nin yıllık 15% oranında büyümesi bekleniyor.

Anahtar bilgiler

-2.1%

Kazanç büyüme oranı

15.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	33.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:1UC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	19	-38	N/A	N/A	4
12/31/2025	10	-40	N/A	N/A	5
12/31/2024	9	-41	N/A	N/A	5
9/30/2024	10	-45	-38	-38	N/A
6/30/2024	8	-47	-39	-39	N/A
3/31/2024	7	-50	-39	-39	N/A
12/31/2023	5	-51	-40	-40	N/A
9/30/2023	4	-52	-40	-40	N/A
6/30/2023	2	-52	-39	-39	N/A
3/31/2023	0	-52	-41	-41	N/A
12/31/2022	1	-53	-42	-42	N/A
9/30/2022	9	-47	-42	-42	N/A
6/30/2022	12	-49	-42	-42	N/A
3/31/2022	14	-46	-39	-39	N/A
12/31/2021	15	-44	-40	-39	N/A
9/30/2021	7	-47	-36	-35	N/A
6/30/2021	5	-44	-38	-36	N/A
3/31/2021	4	-44	-35	-33	N/A
12/31/2020	3	-45	-33	-32	N/A
9/30/2020	4	-43	-32	-32	N/A
6/30/2020	4	-40	-34	-33	N/A
3/31/2020	4	-38	-33	-33	N/A
12/31/2019	3	-37	-31	-31	N/A
9/30/2019	3	-39	-28	-28	N/A
6/30/2019	2	-45	-26	-25	N/A
3/31/2019	2	-43	-26	-25	N/A
12/31/2018	1	-39	-28	-26	N/A
9/30/2018	1	-38	-26	-24	N/A
6/30/2018	0	-30	N/A	-22	N/A
3/31/2018	N/A	-27	N/A	-18	N/A
12/31/2017	N/A	-23	N/A	-12	N/A
9/30/2017	N/A	-16	N/A	-12	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-10	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1UC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 1UC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 1UC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 1UC şirketinin gelirinin (yıllık 33% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1UC şirketinin gelirinin (yıllık 33% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1UC 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Cue Biopharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Cue Biopharma, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2020

Recent updates

Third quarter 2024 earnings released: US$0.17 loss per share (vs US$0.24 loss in 3Q 2023)

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma, Inc. Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Financial position

Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.29 loss in 2Q 2023)

Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Completeness Index

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.29 loss in 1Q 2023)

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.29 loss in 1Q 2023)

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.11 loss per share (vs US$1.49 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.31 loss in 3Q 2022)

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

New minor risk - Market cap size

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.29 loss per share (vs US$0.37 loss in 2Q 2022)

Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million.

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.44 loss in 1Q 2022)

Full year 2022 earnings released: US$1.49 loss per share (vs US$1.41 loss in FY 2021)

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding

Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.33 loss in 2Q 2021)

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought €98k worth of stock

U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.41 loss in 1Q 2021)

Cue Biopharma, Inc., Annual General Meeting, Jun 09, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.34 loss in 3Q 2020)

Cue Biopharma, Inc. Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

Cue Biopharma, Inc Grants U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.38 loss in 2Q 2020)

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

Cue Biopharma to Present A Corporate and Clinical Progress Update At the Upcoming Jefferies Virtual Healthcare Conference

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.48 loss in 1Q 2020)

Cue Biopharma Reports Confirms Partial Response in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

Cue Biopharma, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2020

Revenue misses expectations

Full year 2020 earnings released: US$1.56 loss per share (vs US$1.67 loss in FY 2019)

Cue Biopharma, Inc. Announces Executive Changes

Cue Biopharma, Inc. Appoints Dr. Matteo Levisetti as Senior Vice President of Clinical Development, Effective February 22, 2021

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA

New 90-day low: €9.95

Independent Director recently bought €70k worth of stock

Cue Biopharma, Inc. Extends Research Collaboration for the Development of Immuno-Stat Biologics for the Treatment of Defined Autoimmune Diseases with Merck

New 90-day low: €10.80

Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

Independent Director recently bought €129k worth of stock

New 90-day low: €12.80

Cue Biopharma, Inc. Announces Appointment of Tamar Howson to Board of Directors

New 90-day low - €15.50

First half earnings released

New 90-day low - €17.90

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin